All In Biotech

Drug Trial Radar · NCT04244084

Clinical Trial of Efficacy and Safety of ММН-407 in Acute Respiratory Viral Infection

Multicenter Double-blind Placebo-controlled Parallel Group Randomized Clinical Trial of Efficacy and Safety of MMH-407 in the Treatment of Acute Respiratory Viral Infection

Last checked: Nov 19, 2026Latest source record: May 17, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 240 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

240

Actual

Start

Oct 8, 2019

Primary completion

Apr 9, 2020

Study completion Apr 9, 2020

Sponsor

Lead sponsor
Materia Medica HoldingIndustry
Sponsor type
Industry
First posted
Jan 28, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the efficacy and safety of ММН-407 in treatment of acute respiratory viral infection (ARVI).

Conditions

  • Viral Respiratory Infection

Interventions

  • MMH-407Drug

    Oral use.

  • PlaceboDrug

    Oral use.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to Resolution of Acute Respiratory Viral Infection (ARVI) SymptomsTime frame: 14 days of observation.

Locations

26 sites in 1 country. Site status is shown where the registry gives one.

  • Altai State Medical University, Department of Faculty Therapy with a course of immunology and allergology

    Barnaul, Russia

  • City Hospital #5

    Barnaul, Russia

  • Belgorod State National Research University, Hospital Therapy Department

    Belgorod, Russia

  • Road Clinical Hospital at Chelyabinsk station of JSC Russian Railways

    Chelyabinsk, Russia

  • City Clinical Hospital #9 of the Ministry of Health of the Udmurt Republic

    Izhevsk, Russia

  • Kazan State Medical University, Internal Medicine Department

    Kazan', Russia

  • Kazan State Medical University, Professorial clinic

    Kazan', Russia

  • Kuban State Medical University, Infectious Diseases and PhthisiopulmonologyDepartment

    Krasnodar, Russia

  • Central Clinical Hospital of the Russian Academy of Sciences

    Moscow, Russia

  • Moscow State Medical and Dental University named after A.I. Evdokimov, Pulmonology Laboratory

    Moscow, Russia

  • City Clinical Hospital #10 of the Kanavinsky District of Nizhny Novgorod

    Nizhny Novgorod, Russia

  • Road Clinical Hospital at the station Nizhny Novgorod of JSC Russian Railways

    Nizhny Novgorod, Russia

  • Podolsk City Clinical Hospital # 3

    Podolsk, Russia

  • City Emergency Hospital Rostov-on-Don

    Rostov-on-Don, Russia

  • Ryazan State Medical University named after academician I.P. Pavlov, Department of Outpatient Therapy and Preventive Medicine

    Ryazan, Russia

  • Vvedensky City Clinical Hospital

    Saint Petersburg, Russia

  • City Polyclinic #25 of the Nevsky District

    Saint Petersburg, Russia

  • Medical Center "Reavita Med SPb"

    Saint Petersburg, Russia

  • Road Clinical Hospital of JSC Russian Railways

    Saint Petersburg, Russia

  • City Polyclinic #51

    Saint Petersburg, Russia

  • City Polyclinic #34

    Saint Petersburg, Russia

  • City Polyclinic #43

    Saint Petersburg, Russia

  • Samara City Hospital #4

    Samara, Russia

  • Scientific Medical Center for General Therapy and Pharmacology

    Stavropol, Russia

  • Bashkir State Medical University, Internal Medicine Department

    Ufa, Russia

  • Volgograd State Medical University

    Volgograd, Russia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.